Pediatric dosage recommendations for LTRAs are summarized in Table 2. Patient profiles containing dosages not conforming to these recommendations will be reviewed.
Table 2. LTRA Pediatric Dosage Recommendations1-4
| Drug Nam |
Dosage Form/Strength |
Treatment Indication |
Maximum Recommended Dosage |
| montelukast (Singulair®, generics) |
10 mg tablets, 4 mg, 5 mg chewable tablets, 4 mg oral granule packets |
asthma |
- adolescents greater than or equal to 15 years of age:
- 10 mg once daily in the evening (as tablet)
- children 6-14 years of age:
- 5 mg once daily in the evening (as chewable tablet)
- children 2-5 years of age:
- 4 mg once daily in the evening (as chewable tablet or oral granules)
- children 12–23 months of age:
- 4 mg once daily in the evening (as oral granules)
|
| |
|
prophylaxis, exercise-induced bronchoconstriction |
adolescents greater than or equal to 15 years of age:
- 10 mg as a single dose, at least 2 hours before exercise; dose should not be repeated within 24 hours of previous dose
children 6 to 14 years of age:
- 5 mg (as chewable tablet) as a single dose, at least 2 hours before exercise; dose should not be repeated within 24 hours of previous dose
|
| |
|
seasonal allergic rhinitis |
- adolescents greater than or equal to 15 years of age:
- children 6-14 years of age:
- 5 mg daily (as chewable tablet)
- children 2-5 years of age:
- 4 mg daily (as chewable tablet or oral granules)
|
| |
|
perennial allergic rhinitis |
- adolescents greater than or equal to 15 years of age:
- children 6-14 years of age:
- 5 mg daily (as chewable tablet)
- children 2-5 years of age:
- 4 mg daily (as chewable tablet or oral granules)
- children 6-23 months of age:
- 4 mg daily (as oral granules)
|
| zafirlukast (Accolate®, generics) |
10 mg, 20 mg tablets |
asthma |
- adolescents greater than or equal to 12 years of age:
- 20 mg twice daily
- children 5-11 years of age:
|
